<DOC>
	<DOCNO>NCT02135510</DOCNO>
	<brief_summary>In phase III non-inferiority trial , aim evaluate whether metoclopramide palonosetron prophylactic antemetic treatment non-inferior dexamethasone regard efficacy prevent delay chemotherapy-induced nausea vomiting ( CINV ) induce non- anthracyclines plus cyclophosphamide ( AC ) base moderately emetogenic chemotherapy ( MEC ) .</brief_summary>
	<brief_title>MEtoclopramide , DExamethasone Axoli Prevent Delay Chemotherapy-induced Nausea Vomiting Moderately Emetogenic Non-AC-based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Metoclopramide</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Patient diagnose histologically cytologically confirm solid cancer Starting first cycle chemotherapy moderate emetogenic risk , include combination anthracycline plus cyclophosphamide Age ≥ 18 WHO ≤ 1 Patient able understand speak Dutch Patient nausea and/or vomit 48 hour start chemotherapy treatment Patient submit concomitant radiotherapy submit radiotherapy 15 day start chemotherapy plan receive radiotherapy 8 day administration chemotherapy Patient concomitant severe comorbidy , : Intestinal obstruction Active peptic ulcer Hypercalcemia Uncontrolled diabetes mellitus Pheochromocytoma Tardive dyskinesia Epilepsia Active infective disease Brain leptomeningeal metastasis Psychiatrical disorder Parkinsonism Current use corticosteroid ( similar prednisone ≥ 10 milligram per day ) Current alcohol abuse Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>